strong patents, weak patents and evergreening: should patents for drugs be challenged more often? Giancarlo Del Corno Studio Legale Sena e Tarchini

Similar documents
Why patents DO matter to YOUR business

TRIPS and Access to Medicines. WR Briefing

UNCITRAL Third International Colloquium on Secured Transactions Session on Contractual Guide on IP Licensing (Vienna, March 3, 2010)

TRAINING SEMINAR PHARMACEUTICALS AND INTELLECTUAL PROPERTY ACCESS TO MEDICINE: Exploitation of pharmaceutical patents: compulsory licences SESSION 4

Carnegie Endowment for International Peace

Standing Committee on the Law of Patents Twenty-Sixth Session

Flexibilities in the Patent System

WHO workshop on IP and Vaccines. Geneva 19 th -20 th April Introduction to the IP issues Christopher Garrison Consultant to WHO

Question Q 159. The need and possible means of implementing the Convention on Biodiversity into Patent Laws

Patent Working Requirements Historical and Comparative Perspectives

Strategic Patenting and Registration of Healthcare Products

Patents and Business Strategies A Patent Attorney s Perspective

PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IN CANADA CHRONOLOGY OF SIGNIFICANT EVENTS

Patent Misuse. History:

Topic 3 - Chapter II.B Primary consideration before drafting a patent application. Emmanuel E. Jelsch European Patent Attorney

Public Research and Intellectual Property Rights

Why patents DO matter to YOUR business

Patent Due Diligence

Issues at the Intersection of IP and Competition Policy

AN OVERVIEW OF THE UNITED STATES PATENT SYSTEM

TRIPS Post Grant Flexibilities: Key Exceptions to Patent Holders' Rights. David Vivas Eugui

TRIPS-Plus Provisions and Access to Technologies:

Slide 15 The "social contract" implicit in the patent system

Topic 2: Patent-related Flexibilities in Multilateral Treaties and Their Importance for Developing Countries and LDCs

BIPF Munich. South Africa Enforcement of Pharmaceutical Patents and the New Draft IP Policy

Building a Competitive Edge: Protecting Inventions by Patents and Utility Models

Patenting Strategies. The First Steps. Patenting Strategies / Bernhard Nussbaumer, 12/17/2009 1

Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities

TRIPs & PATENTS. In 1899, Mr. Charles H. Duell, Director of US Patent office said Everything that can be invented, has (already) been invented.

Indian Pharmaceutical Alliance. Responses to the issues raised in the Discussion Paper on the Utility Model

Flexibilities in the Patent System

Slide 25 Advantages and disadvantages of patenting

Dr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board

Evaluating a Report of Invention & Licensing. Technology Development Boot Camp Peter Liao March 25, 2013

Intellectual Property and Sustainable Development

Regional Seminar on the Effective Implementation and Use of Several Patent-Related Flexibilities

What s in the Spec.?

HOW TO READ A PATENT. To Understand a Patent, It is Essential to be able to Read a Patent. ATIP Law 2014, All Rights Reserved.

Bangkok, August 22 to 26, 2016 (face-to-face session) August 29 to October 30, 2016 (follow-up session) Claim Drafting Techniques

April 21, By to:

IPRs and Public Health: Lessons Learned Current Challenges The Way Forward

Patents, Standards and Antitrust: Patent Pools

TRIPS and Access to Medicines. The Story so far

IIPTA. Role of Intellectual Property Rights in Biotechnology Industry. Launch a Career. Be Awesome

AN OVERVIEW OF THE UNITED STATES PATENT SYSTEM

2.5.2 NON-DISCRIMINATION (ARTICLE 27.1)

CS 4984 Software Patents

Lundbeck s view on the EU IP systems

Research Patents in Biotech SMEs

Statement by the BIAC Committee on Technology and Industry on THE IMPACT OF INTELLECTUAL PROPERTY PROTECTION ON INNOVATION AND TECHNOLOGY DEVELOPMENT

THE UNIVERSITY OF AUCKLAND INTELLECTUAL PROPERTY CREATED BY STAFF AND STUDENTS POLICY Organisation & Governance

Intellectual Property

11th Annual Patent Law Institute

Protecting Your Trade Secrets in Silicon Valley and Beyond

Patent application strategy when, where, what to file?

Business Method Patents, Innovation, and Policy

DOC-CAREERS II Project, Final conference Brussels 2012 University-Industry Intellectual property rights: Balancing interests

Outline 3/16/2018. Patent Basics for Inventors, Entrepreneurs, and Start-ups.

"Competition Policy and Intellectual Property Rights in the Republic of Latvia since 1991" (the working title)

TRIPS, FTAs and BITs: Impact on Domestic IP- and Innovation Strategies in Developing Countries

The MHRD Chair on IPR National Law School of India University

Ref: Overview of the implementation of the TRIPS Agreement (patents) in the EPC contracting states and observer countries

Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities

Introduction to IP: Some Basics of Patents, Trademarks, & Trade Secrets

NHS Greater Glasgow and Clyde Health Board. Policy on the Management of Intellectual Property

Observations from Pharma

Intellectual Property Management - How to capture, protect and exploit your ideas

Under the Patronage of His Highness Sayyid Faisal bin Ali Al Said Minister for National Heritage and Culture

Developing Countries in the Globalization of Pharmaceutical Patenting

Patent Basics for Inventors, Entrepreneurs, and Start-ups. Ned Landrum Patent Training Advisor STEPP Program Manager

Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development

IS STANDARDIZATION FOR AUTONOMOUS CARS AROUND THE CORNER? By Shervin Pishevar

Lexis PSL Competition Practice Note

Clarity of thought: telling Congress how to improve 101

19 Progressive Development of Protection Framework for Pharmaceutical Invention under the TRIPS Agreement Focusing on Patent Rights

POLICY PHILOSOPHY DEFINITIONS AC.2.11 INTELLECTUAL PROPERTY. Programs and Curriculum. APPROVED: Chair, on Behalf of SAIT s Board of Governors

International IP. Prof. Eric E. Johnson. General Principles

WIPO-IFIA INTERNATIONAL SYMPOSIUM ON THE COMMERCIALIZATION OF INVENTIONS IN THE GLOBAL MARKET

Technology Transfer and Intellectual Property Best Practices

Intellectual Property Rights in the Academic and Research Environment

5 th Annual Pharma IPR Conference 2016

Innovation Office. Intellectual Property at the Nelson Mandela University: A Brief Introduction. Creating value for tomorrow

MULTIPLE ENTRY CONSOLIDATED GROUP TSA USER AGREEMENT

Issues and Possible Reforms in the U.S. Patent System

Introduction to Intellectual Property

Nitya Nanda. The Energy and Resources Institute (TERI)

Patent Basics for Inventors, Entrepreneurs, and Start-ups

Submission to the Productivity Commission inquiry into Intellectual Property Arrangements

Intellectual Property

US Patent Litigation Trends in Cloud Computing IPlytics GmbH

Patent Drafting Strategy. Zeinab A. Osman, PhD Institute of Engineering Research and Materials Technology National Center for Research

Settlement of Pharma Disputes and Competition Law in Korea

B) Issues to be Prioritised within the Proposed Global Strategy and Plan of Action:

PROTECTING INVENTIONS: THE ROLE OF PATENTS, UTILITY MODELS AND DESIGNS

Intellectual Property

Intellectual Property and UW Technology Transfer. Patrick Shelby, PhD Technology Manager October 26, 2010

FÉDÉRATION INTERNATIONALE DES CONSEILS EN PROPRIÉTÉ INDUSTRIELLE. 24 February 2011 Via electronic filing

Panel Report Canada - Patent Protection of Pharmaceutical Products (WT/DS114/R)

A conversation on Patent Quality

Alternatives to the patent system used to support R&D Efforts. James Love WIPO Expert Forum on International Technology Transfer February 17, 2015

Transcription:

strong patents, weak patents and evergreening: should patents for drugs be challenged more often? 1

definition of strong vs. weak patent evergreening patents in terms of validity; in terms of extent of protection; evergreening patents; false problem under the profile of competition; 2

patent and competition absence of parallelism between exclusive rights conferred by a patent and an automatic existence of monopoly; patent does not confer a position, excluding or narrowing by itself the competition and giving therefore a substantial marginal utility; relevant market is not exclusively represented by the patented product/process; determination of the presence/absence of competition has to be referred to a broader market where other substitutes may be offered; 3

patent and competition several studies have confirmed that in sectors in which the research and development is particularly relevant, there is a strong competition in terms of innovation and realization of novel products and technology; competition is effective on this field; important patent protection favours innovation, selecting the competition on the basis of novel products and technology; no patent protection addresses the competition on other issues, such as for example price competition; choice is between innovation vs. availability of goods at marginal costs; 4

extent of protection and compulsory licence patent confers a right of exclusivity, impeding competitors from exploiting the results of their research and development activity; current trend is addressed to reduce such right in favour of monetary reward such as for example licences; conclusion valid for some technology (i.e. communication) and for the so-called standard patents ; compulsory licence favours competition in terms of innovation; 5

extent of protection and compulsory licence granting of a patent does not impede the competition to go ahead and on the contrary increases the research and development activity and forces the entrepreneurs to get novel results and to improve the quality of the products; article 31 of the Trips agreement and similar provision in other national laws; use is authorized to permit the exploitation of a patent which cannot be exploited without infringing another earlier patent; second invention involves an important technical advance of considerable economic significance in relation to the first invention; Studio Legale Sena e Tarchini 6

extent of protection and compulsory licence the owner of the first invention is entitled to a crosslicence on reasonable terms to use the second invention the use authorized in respect of the first invention shall be non-assignable except with the assignment of the second invention; the reduction of the patent protection may lead the entrepreneurs to shift from a patenting (and therefore public) policy to an utilization of the relative results in a secrecy regime, also considering the adequate protection of undisclosed information; 7

choice of the Judge Patent Courts: more general knowledge as to patent law, case by case approach, ability to fine vexatious litigations; Competition Authorities: less experience in patent fundamentals, change of the existing laws, price competition approach; patents for drugs be challenged more often before Patents Courts. 8